H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Elevation Oncology to $6 from $1.50 and keeps a Buy rating on the shares. The analyst believes Elevation could provide meaningful development updates regarding EO-3021 during the first half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELEV:
